Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 21160469)

1.

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.

Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F.

Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15. No abstract available.

PMID:
21160469
2.

Striking the right balance.

[No authors listed]

Nat Rev Drug Discov. 2006 Nov;5(11):879. No abstract available.

PMID:
17117516
3.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
4.

Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.

Leong J, McAuslane N, Walker S, Salek S.

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1004-12. doi: 10.1002/pds.3464. Epub 2013 Jun 5.

PMID:
23740622
5.

The identification of benefit in medical intervention: an overview and suggestions for process.

Stang PE, Pham SV, Kinchen K, Raff SB, Mussen F, Gondek K.

Am J Ther. 2008 Sep-Oct;15(5):495-503. doi: 10.1097/MJT.0b013e31816b8fff. Review.

PMID:
18806527
6.

Manufacturing uncertainty: adverse effects of drug development for women.

Peppin P.

Int J Law Psychiatry. 2003 Sep-Oct;26(5):515-32. No abstract available.

PMID:
14522223
7.

Drug safety, pharmacoepidemiology, and regulatory decision making.

Nelson RC.

Drug Intell Clin Pharm. 1988 Apr;22(4):336-44.

PMID:
3371198
8.

Communicating the risks of medicines: time to move forward.

Dal Pan GJ.

Med Care. 2012 Jun;50(6):463-5. doi: 10.1097/MLR.0b013e31825852f0. No abstract available.

PMID:
22581011
9.

Experience with a failed postmarketing drug surveillance program.

Hollister LE, Overall JE.

J Clin Pharmacol. 1984 Jan;24(1):3-5. No abstract available.

PMID:
6707232
10.

[Communication and transparency concerning risk-benefit analysis in public health: the example of medication].

Lehner JP, Meyer F, Juillet Y.

Therapie. 2001 Jul-Aug;56(4):335-9. French.

PMID:
11677849
11.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
12.

Post-marketing surveillance or drug acceptability study?

Barnett DB, Woods KL.

Br J Clin Pharmacol. 1987 Sep;24(3):281-2. No abstract available.

13.

[Novel therapeutics risk management].

Hagemann U.

Z Evid Fortbild Qual Gesundhwes. 2009;103(5):269-72. German.

PMID:
19645340
14.

Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.

Swain E, Morgan S, Brewster W, Kauser S.

Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):232-7. doi: 10.1002/pds.1898.

PMID:
20033909
15.

[Physician and pharmaceutical industry. II. Postmarketing surveillance].

Offerhaus L.

Ned Tijdschr Geneeskd. 1992 Jan 4;136(1):36-41. Dutch. No abstract available.

PMID:
1728761
16.

The US drug safety system: role of the pharmaceutical industry.

Gibson BR, Suh R, Tilson H.

Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):110-4.

PMID:
17724741
17.

["There are clear criteria for product surveillance studies"].

Throm S.

MMW Fortschr Med. 2009 Aug 20;151(34-35):7. German. No abstract available.

PMID:
19771777
18.

Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.

Quartey G, Wang J.

Pharm Stat. 2012 Jan-Feb;11(1):82-5. doi: 10.1002/pst.497. Epub 2011 Oct 13.

PMID:
21997832
19.

Post-marketing surveillance in the UK (1984).

Lawson DH.

Br J Clin Pharmacol. 1986;22 Suppl 1:71S-75S. No abstract available.

20.

Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.

[No authors listed]

Consum Rep. 2006 Jan;71(1):34-9. No abstract available.

PMID:
16491527
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk